Showing 893 results
-
Media Release /Approval for moderate to severe pediatric patients six years and older is based on pivotal trial data showing Cosentyx demonstrated superior improvements of skin symptoms compared to placebo(1)…
-
Media Release /MONALEESA-3 median overall survival (OS) results of 53.7 months underscore that Kisqali offers more life to postmenopausal women with HR+/HER2- metastatic breast cancer (MBC) in addition to the OS…
-
Media Release /Primary analysis of ELARA trial demonstrated a 66% complete response rate and 86% overall response rate with one-time Kymriah infusion(1) Robust response observed in heavily pretreated patients in…
-
Media Release /Tislelizumab demonstrated a 30% reduction in the risk of death and extended median overall survival by 2.3 months compared to chemotherapy in advanced or metastatic esophageal squamous cell…
-
Media Release /Tabrecta® (capmatinib) showed a median overall survival (OS) of 20.8 months in treatment-naïve patients and 13.6 months in previously-treated patients in first published mature data1,2 Tabrecta…
-
Story /At Novartis, our common humanity is what connects all of us. We will continue to stand in solidarity with all people who find themselves in the path of injustice, inequity or violence. The Day of Reflection, Forward Together is an opportunity for everyone to engage in listening and learning.
-
Story / -
Story /The Novartis US Foundation partners with local groups to improve healthcare in underserved communities, including by expanding use of telemedicine.
-
Media Release /If approved, Xolair self-administration would offer a more flexible option to help select patients manage their treatment needs Filing acceptance is based on the well-established efficacy and…
-
Media Release /Xolair is the first biologic for the treatment of nasal polyps that targets and blocks immunoglobulin E (IgE), a key driver of inflammation Xolair is now FDA-approved across three diseases and in…
